Last reviewed: April 2026
Edition genomics AI for diseases of oeil and of sang.
Editas Medicine is an AI-powered cell & gene therapy solution that delivers intelligent automation and data-driven insights. It is designed for cell therapy developers, immunologists, clinical teams across the biotechnology and life sciences sector. Founded in 2016, the company is recognized for its curative potential and personalized therapy.
Editas Medicine is best suited for cell therapy developers, immunologists, clinical teams. Public company (EDIT) pricing for biotech teams.
Official website: Editas Medicine
Compare Editas Medicine with other platforms
The platform is designed to address the specific challenges faced by Biotech organizations. Key users include Cell therapy developers, Immunologists, Clinical teams who rely on the platform for ocular gene editing, sickle cell ai, crispr therapies. In the rapidly evolving Biotech landscape, Editas Medicine stands out by combining cell & gene therapy capabilities with industry-specific features that address the unique challenges of ocular gene editing, sickle cell ai, crispr therapies. The platform enables Cell therapy developers and Immunologists to transition from manual, error-prone processes to automated, data-driven workflows that deliver consistent results at scale. Compared to alternatives in the cell & gene therapy space, Editas Medicine differentiates itself through its focus on Biotech use cases, and Public company (EDIT) that accommodates organizations at different stages of their AI adoption journey.
Before adopting Editas Medicine or any Cell & Gene Therapy solution for your biotech workflows, it is important to assess how the platform fits your specific requirements. Start by mapping your highest-priority pain points — whether that is reducing manual tasks, improving data accuracy, scaling customer interactions, or accelerating time to insight. Editas Medicine positions itself as a Cell & Gene Therapy solution, having been in the market since 2016, so evaluate whether its feature set directly addresses those pain points rather than relying on feature-list comparisons alone.
Request a live demo or proof-of-concept trial before committing to an annual contract. During the trial, measure concrete outcomes: task completion time, error rates, user adoption speed, and integration friction with your existing stack. Compare these metrics against at least two alternative vendors in the Cell & Gene Therapy space to establish a meaningful benchmark. Editas Medicine uses a Public company (EDIT) pricing model — make sure you understand the total cost of ownership including implementation, training, and any per-seat or usage-based fees.
Confirm deployment options meet your IT and compliance requirements. Verify what compliance certifications and data-handling guarantees the vendor provides, especially for regulated biotech environments. Also ask about the vendor's SLA for uptime, support response times, and the data export process should you decide to switch providers in the future.
Editas Medicine is a Cell & Gene Therapy platform designed for biotech organizations. Edition genomics AI for diseases of oeil and of sang.
Editas Medicine scores 8.7/10 on AI Scanner's independent evaluation. The score reflects performance (30%), usability (25%), pricing value (25%), and versatility (20%). Scores are updated monthly based on product changes, user feedback, and competitive benchmarking across Cell & Gene Therapy tools. Read our full scoring methodology.
The top alternative to Editas Medicine on AI Scanner is CRISPR Therapeutics with a score of 9.1/10. Other alternatives include Intellia Therapeutics, Nkarta, Sana Biotechnology. Compare all alternatives.
Editas Medicine is designed for enterprise organizations. Its Public company (EDIT) pricing model scales with team size and usage requirements. We recommend running a pilot with your actual workflows before committing to a full deployment.
Editas Medicine uses a Public company (EDIT) pricing model. For the most accurate pricing, request a custom quote directly from the vendor. Pricing may vary based on deployment scale, feature tier, and contract length. Always factor in implementation and training costs when comparing total cost of ownership against competitors.
How We Score: AI Scanner evaluates platforms across four dimensions - Performance (30%), Usability (25%), Pricing Value (25%), and Versatility (20%). Scores are updated monthly. Read our full methodology.